Abid Majid, MD
Critical Care Medicine · San Pablo, CANPI 1902828486
Payments from drug & device makers
Across 565 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Boehringer Ingelheim$2K
- GSK$2K
- Mylan Specialty L.p.$851
- Sunovion Pharmaceuticals Inc.$593
- Harmony Biosciences LLC$252
- plus $3K from 26 others
What the payments were for
- Food & beverage$12,23898%
- Education$2602%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 141 | $3,566 |
| Boehringer Ingelheim | 97 | $2,457 |
| GSK | 126 | $2,146 |
| Mylan Specialty L.p. | 32 | $851 |
| Sunovion Pharmaceuticals Inc. | 48 | $593 |
| Harmony Biosciences LLC | 16 | $252 |
| Regeneron Healthcare Solutions, Inc. | 11 | $252 |
| Viatris Specialty LLC | 8 | $234 |
| Intuitive Surgical | 2 | $205 |
| United Therapeutics Corporation | 11 | $202 |
| Sanofi | 9 | $202 |
| Amgen | 7 | $194 |
| Johnson & Johnson | 1 | $159 |
| Advanced Respiratory, Inc | 11 | $144 |
| Merck | 5 | $139 |
| Gilead | 7 | $135 |
| Sanofi-aventis U.S. LLC | 2 | $132 |
| Baxter Healthcare | 7 | $100 |
| Genentech USA, Inc. | 6 | $96 |
| Insmed, Inc. | 3 | $77 |
| Vanda Pharmaceuticals Inc. | 3 | $74 |
| Mallinckrodt Hospital Products Inc. | 2 | $48 |
| Inspire Medical Systems, Inc. | 1 | $43 |
| Itamar Medical Inc | 1 | $29 |
| Verona Pharma, Inc. | 1 | $26 |
| Pulmonx Corporation | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $23 |
| Electromed, Inc. | 1 | $21 |
| Resmed Corp | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Circassia Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$472
- NUCALA$370
- OFEV$226
- N/A$159
- FASENRA$125
- AIRSUPRA$122
- TRELEGY ELLIPTA$118
- Da Vinci Surgical System$108
How this compares
$12,497 in reported general payments places this provider in the 85th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 28 | $327,197 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 155 | $113,607 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $50,506 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $31,766 |
| Spiriva RespimatTiotropium Bromide | 21 | $11,695 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $11,201 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $8,896 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 233 | $8,644 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $8,591 |
| BelsomraSuvorexant | 12 | $5,194 |
| BreynaBudesonide/Formoterol Fumarate | 21 | $3,590 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,690 |
| Ventolin HfaAlbuterol Sulfate | 39 | $2,295 |
| Proair RespiclickAlbuterol Sulfate | 12 | $1,209 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $1,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $2,457 | $350,09360 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $2,146 | $162,860247 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,566 | $53,19556 claims |
| MerckBelsomra | $139 | $5,19412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 715 critical care medicine providers in California.
Other critical care medicine in San Pablo
- Rafael LupercioRedding$14.6M
- Timothy AlbertsonSacramento$7.6M
- Carolyn CalfeeSan Francisco$5M
- Bassam YaghmourOrange$4.4M
- Cedric Franklin RutlandRiverside$3.2M
- Alex HakimLos Angeles$946K
- Praveen AkuthotaSan Diego$841K
- Wael El MaraachliSan Diego$751K
- Stephen RuossStanford$635K
- Bryon QuickOakland$594K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.